Cabel, L., Fuerea, A., Lacroix, L., Baldini, C., Martin, P., Hollebecque, A., . . . Verlingue, L. (2018). Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. Oncotarget.
Chicago Style citaatCabel, Luc, et al. "Efficacy of Histology-agnostic and Molecularly-driven HER2 Inhibitors for Refractory Cancers." Oncotarget 2018.
MLA citatieCabel, Luc, et al. "Efficacy of Histology-agnostic and Molecularly-driven HER2 Inhibitors for Refractory Cancers." Oncotarget 2018.
Let op: Deze citaties zijn niet altijd 100% accuraat.